Clinical Trial Documentation & Plan Support for a Biopharmaceutical Company

Context

A biopharmaceutical organisation needed structured regulatory documentation support for clinical-trial-related materials intended for submittal by the client to the U.S. Food and Drug Administration (FDA).

Overview

We prepared the strategic plan and supporting documentation end-to-end for the client’s use. The client remained the party of record for submission and agency interactions.

Approach

1. Clarify document purpose, audience and source evidence with RA stakeholders
2. Author and structure the plan and related writing so technical and clinical inputs form one narrative
3. Iterate with the client’s team on data integrity and risk-aware documentation practices
4. Support the client through to a package the client could submit

Our role

• Translated complex clinical data and technical processes into structured regulatory writing for the client’s use
• Emphasised data integrity and risk-aware documentation practices
• Documentation and strategy support to the client’s regulatory affairs team; the client remained party of record

What mattered

• One coherent clinical–regulatory narrative instead of disconnected drafts
• Data integrity and risk-aware documentation practices inside the client’s processes
• End-to-end plan preparation with the client remaining party of record

Result

We prepared the plan from start to finish. The client submitted it to the U.S. Food and Drug Administration (FDA), and the plan was formally approved by the FDA. The client remained the party of record. This approval related specifically to the plan and was distinct from any separate FDA clearance, approval or authorization of a marketed product.

Notes

• The client remained party of record with the agency
• The stated outcome is for this engagement’s plan
• Described anonymously under our case-study policy

Related

Regulatory support · Biotech & Pharma · How we work